General Information of the Compound
Compound ID
CP0655961
Compound Name
SID50104972
    Show/Hide
Synonyms
AVIVA
DuP-996
Linopirdine
Linopirine
    Show/Hide
Structure
Formula
C26H21N3O
Molecular Weight
391.474
Canonical SMILES
O=C1N(c2ccccc2)c2ccccc2C1(Cc1ccncc1)Cc1ccncc1
    Show/Hide
InChI
InChI=1S/C26H21N3O/c30-25-26(18-20-10-14-27-15-11-20,19-21-12-16-28-17-13-21)23-8-4-5-9-24(23)29(25)22-6-2-1-3-7-22/h1-17H,18-19H2
    Show/Hide
InChIKey
YEJCDKJIEMIWRQ-UHFFFAOYSA-N
CAS
105431-72-9
Physicochemical Property
logP
4.8781
Rotatable Bonds
5
Heavy Atom Count
30
Polar Areas
46.09
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
3
Complexity
30

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 3932
SID: 12014138
ChEMBL ID
CHEMBL319111
DrugBank ID
DB13806
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT06109, Geminin
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000015 SW480 Homo sapiens (Human)  1
1
Potency ~ 1258.9 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( Linopirdine )
Drug Name Linopirdine
Company Bristol-Myers Squibb Pharma Co
Indication
Cognitive impairment
Phase 3
Target(s)
Voltage-gated potassium channel Kv7.3 (KCNQ3)
Modulator